Adrenomedullin Therapy for Moderate-to-Severe COVID-19 Pneumonia: Double-Blind Placebo-Controlled Phase 2a Trial

What Was Tested

This randomized controlled trial paper looks at Adrenomedullin.

Adrenomedullin (AM) is a bioactive peptide that is strongly induced during severe inflammation, including pneumonia and sepsis, and serves as an organ-protective factor.

This multicenter, double-blind, placebo-controlled phase-2a trial evaluated COVID-19 patients with severe (n = 33) and moderate (n = 31) pneumonia in Japan.

Who Took Part

The study group was 19 patients.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and multicenter.

Because people in this Adrenomedullin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Adrenomedullin study, the assignments were hidden from both participants and investigators until the end.

Some patients received a placebo instead of Adrenomedullin, giving a reference point.

More than one site took part, so the patients came from several places.

A time span of 30 days appears in the methods.

What Was Measured

This multicenter, double-blind, placebo-controlled phase-2a trial evaluated COVID-19 patients with severe (n = 33) and moderate (n = 31) pneumonia in Japan.

The primary endpoint was the duration of mechanical ventilation (MV) for severe pneumonia and oxygen support for moderate pneumonia.

The subject headings attached to it are Adrenomedullin, COVID-19 Drug Treatment, COVID-19, SARS-CoV-2, Respiration, Artificial and Japan.

Author keywords: Japanese, mechanical ventilation, phase 2a clinical trial and pneumonia.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Adrenomedullin in 19 patients over 30 days.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2025 (Viruses), a journal based in Switzerland.

More context: the Adrenomedullin compound page, all human trials.